Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion
Introduction
N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) is an N-acetylglucosamine analogue of muramyl dipeptide (MDP). MDP is the smallest fragment of the bacterial cell wall which initiates an immune response in man (Ellouz et al., 1974). MDP and MDP analogues have been identified as having potential clinical utility as vaccine adjuvants (Ellouz et al., 1974), immunostimulators (Tsubura et al., 1988), anti-cancer agents (Utsugi et al., 1991) and antiinflammatory agents (Leclerc et al., 1979) however, MDP is highly pyrogenic in man (Dinarello et al., 1978). GMDP retains the favourable activity of MDP but is less pyrogenic.
Oral administration is desirable for most therapeutic agents, including peptides and proteins, as it avoids the pain and risk of infection associated with parenteral administration and thereby leads to greater patient compliance. The development of peptides and proteins as oral formulations has however, been limited by their low bioavailability when administered via this route. In this regard, initial studies examining the oral bioavailability of (14C)GMDP in beagle dogs have indicated that the absolute bioavailability of GMDP is low (6.7%, unpublished data), however, limited information is available regarding the factors contributing to the poor oral bioavailability.
The low oral bioavailability of GMDP was confirmed in the current study in the rat. The stability of GMDP in the lumen of the gastrointestinal tract and intestinal permeability were subsequently examined and the data reported here lead to the conclusion that the oral bioavailability of GMDP is limited primarily by instability in the lumen of the gastrointestinal tract and low intestinal permeability. The dissolution of GMDP in an aqueous environment is unlikely to contribute to the low oral bioavailability as the peptide is highly water-soluble (1 g of peptide is dissolved in 0.9 ml of water). Consequently formulation strategies which protect the compound from breakdown in the gut and increase the intestinal permeability will likely enhance the oral bioavailability of GMDP.
In the light of these findings, a water-in-oil microemulsion system similar to that previously reported to enhance the oral bioavailability of peptides in rats (Constantinides et al., 1994, Constantinides, 1995, Constantinides et al., 1996) was selected as a prototype delivery system with which to conduct a preliminary bioavailability study. The data described indicate that water-in-oil microemulsion systems may improve the delivery characteristics of peptides when enzymatic/chemical degradation in the lumen of the gut and limited intestinal permeability are the cause of reduced oral bioavailability.
Section snippets
Materials
Three batches of [14C]GMDP (specific activity of 175 μCi/μmole, 194 μCi/μmole and 182 μCi/μmole and one batch of (3H)GMDP (specific activity 1.27 Ci/mmole) were custom synthesised by Auspep Pty. (Parkville, Vic., Australia). Peptech (North Ryde, NSW, Australia) supplied the GMDP. (14C)mannitol (Cat No. NEC 314), (3H)mannitol (Cat No. NET 101) and (14C]diazepam (Cat No. NET 564) were obtained from NEN (Boston, MA). Captex 355 and Capmul MCM were obtained from Abitec (Janesville, WI). Tween 80
Pharmacokinetics of GMDP following intravenous administration
The plasma concentration-time profile for parent (14C)GMDP after i.v. administration (mean±S.D., n=3) is shown in Fig. 1. Total 14C activity is also shown and expressed as ng GMDP equivalents. Total 14C activity may also represent activity associated with species other than [14C]GMDP and therefore, total 14C activity in ng GMDP equivalents will only accurately express GMDP concentration if the only labelled species present is GMDR Limited deviation of the total 14C activity trace from the
Discussion
The low absolute oral bioavailability of (14C)GMDP (8.3±4.4%) found in the current study confirms previous unpublished studies for GMDP in beagle dogs (oral bioavailability 6.7%, unpublished data, Peptech, Sydney) and is consistent with the low oral bioavailability of many peptide-like drugs. The oral bioavailability of peptide-like drugs may be limited by poor dissolution, breakdown in the gastrointestinal (GI) tract prior to absorption, significant first pass metabolism or limited
Acknowledgements
The authors wish to thank Peptech Limited (Australia) for funding, Dr Fiona Dunagan for assessment of this manuscript and Richard Gleisner for his technical assistance.
References (21)
- et al.
How structural features influence the biomembrane permeability of peptides
J. Pharm. Sci.
(1996) - et al.
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
Biochem. Biophys. Res. Commun.
(1974) - et al.
Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brushborder enzymes
Peptides
(1996) - et al.
In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-l-alanyl-d-isoglutamine, muramyl dipeptide for MDP
Cell. Immunol.
(1979) - et al.
Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen
Peptides
(1998) Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects
Pharm. Res.
(1995)- et al.
Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides
Pharm. Res.
(1994) - et al.
Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation
Pharm. Res.
(1996) - et al.
The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues
J. Infect. Dis.
(1978) - et al.
The effect of beta-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers
Pharm. Res.
(1997)
Cited by (56)
Stability and release of bioactives from liposomes
2022, Liposomal Encapsulation in Food Science and TechnologyInteraction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs
2021, Journal of Controlled ReleaseCitation Excerpt :Since different dilution conditions resulted in different concentrations of drug entering the intestine in the perfusate, drug flux profiles were normalised to the initial nominal luminal concentration employed under the simple perfusion conditions (3.6 mg/mL). Studies were conducted as a series of one-way parallel studies in male Sprague–Dawley rats (265–330 g) (n = 3–5 per group) as described previously [29,30]. Rats were anaesthetized using isoflurane (5% v/v induction, 2.5% v/v maintenance) during surgical procedures.
Cluster of differentiation 14 and toll-like receptor 4 are involved in the anti-inflammatory effects of tyrosol
2019, Journal of Functional FoodsA cell-based test system for the assessment of pharmacokinetics of NOD1 and NOD2 receptor agonists
2018, International ImmunopharmacologyCitation Excerpt :Therefore, the low recovery of drugs at 3 min after injection to rabbits (Fig. 2E, F) may be due to their binding to, or endocytosis by, blood cells or endothelium. GMDP was stable in normal rabbit serum during at least 2 h of incubation at 37 °C (Fig. 2G), consistent with earlier reports [21,22]. In case of GS-triDAP, a 2-fold decrease of concentration was observed at 2 h (Fig. 2H), indicating break-down by serum peptidases.
The use of low molecular weight protamine to enhance oral absorption of exenatide
2018, International Journal of PharmaceuticsCitation Excerpt :Furthermore, LMWP and insulin form conjugates that greatly improve bioavailability in vivo compared with insulin alone (He et al., 2013). Enzymatic degradation in the gastrointestinal tract and permeability in the intestinal epithelium are the two major obstacles to oral delivery (Lyons et al., 2000). A NP drug delivery system can solve these two issues.
Developments of Polysorbate (Tween) based microemulsions: Preclinical drug delivery, toxicity and antimicrobial applications
2017, International Journal of PharmaceuticsCitation Excerpt :Microemulsions are believed to protect the drug from hydrolysis and various other enzymatic degradations, which ultimately led to improve the bioavilability of a drug. The maximum degradation is observed through oral route and by using radio-labelled N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP), Lyons et al. (Lyons et al., 2000) evaluated the factors affecting the poor bioavailability of the drug by the oral route. The stability analysis in the lumen of the gastrointestinal (GI) tract along with the evaluation of permeability coefficient (papp) of drug was performed.